CA
NZ
UK
AU
IND
US
Adjusted earnings grew 12% as reported and 13% in constant currency, helped by higher variable investment income, broadVolumegrowth and favorable underwriting. Adjusted net investment income increased 10% to USD 6.0 billion. Group Benefits adjusted earnings rose 15% to USD 523 million, Asia rose 11%, …
Key HighlightsTheGAAPnet loss was USD 111.7 million, or USD 1.19 per basic and diluted common share, againstNet Incomeof USD 48.1 million a year earlier.Distributable earnings, a non-GAAP measure, were USD 26.4 million, or USD 0.26 per basic share, up from USD 12.2 million, or …
Nonregulated Energy contributed USD 6.7 million versus USD 6.3 million, and Transmission Investments USD 2.9 million versus USD 2.4 million, thanks to higher equity earnings from theInvestmentin ATC. The All Other segment earned USD 2.5 million, withVenture Capitalfund gains cited for the nine-month increase. …
Cost of revenue fell 8% to USD 64.0 million because traffic acquisition costs dropped USD 9.1 million as less revenue was reported gross. Total expenses were USD 153.7 million against USD 154.5 million, so income from operations rose 102% to USD 50.5 million. The …
Total production averaged 117.3 thousand barrels of oil equivalent per day, up from 100.5, and oil volumes grew 24% to 49.1 thousand barrels per day. The Giddings area grew 23%, with oil there up 39%, and made up 83% of company volumes. Only a …
Gross margin was 47.7% against 46.6% a year earlier, and GAAP operating margin rose to 23.1% from 14.0%. GAAP net income of USD 236 million was roughly triple the prior-year USD 74 million (calculated), and nine-month GAAP net income reached USD 495 million versus …
Aggregates gross profit fell 4% to USD 512 million, with the company citing higher depreciation, depletion and amortization and energy-related costs. Total depreciation, depletion and amortization in cost of revenues was USD 231 million against USD 143 million. Acquisition, divestiture and integration expenses were …
Cost of operations rose 19.0% to USD 182.4 million, soGross Profitgrew 17.6% to USD 29.8 million. Selling, general and administrative expenses rose 3.5% to USD 22.0 million but fell to 10.4% of sales from 11.9%. The effective tax rate dropped to 19.2% from 28.4% …
Operating expenses were USD 79.9 million against USD 71.4 million, withResearch and Developmentat USD 68.9 million and general and administrative at USD 11.0 million. The R&D rise includes USD 17.0 million of accrued milestone license fees owed to MHKDG on expected BLA acceptance and …
The company develops lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled or resistant hypertension. It submitted its new drug application in December 2025, the FDA accepted it, and the target action date is December 22, 2026. The filing says an advisory committee meeting is …
Please wait processing your request...